孤立的口服CD30+/CD4+ CAR+ t细胞淋巴瘤放疗后长期缓解。

IF 12 1区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Molecular Therapy Pub Date : 2025-09-02 DOI:10.1016/j.ymthe.2025.08.043

Evandro Bezerra,Ludmila Lupu,Marcos de Lima,Lena Pfaller,Alison Neal,Nelly R Hajizadeh,Qiuhong Zhao,Martin Beibel,Catherine Chung,Myriam Lemmens,Austin Sim,Mevion Oertli,Timothy Voorhees,Rebecca Bohnert,Nathan Denlinger,Yoann Gilbart,Lara Bontadelli,Laura Monovich,Jennifer Willert,Daniel Stover,Jingbo Gao,Li Li,Stefan Reinker,Ulrike Naumann,Hans D Menssen,Daniel Jones,Silvana Libertini,Jonathan E Brammer

{"title":"孤立的口服CD30+/CD4+ CAR+ t细胞淋巴瘤放疗后长期缓解。","authors":"Evandro Bezerra,Ludmila Lupu,Marcos de Lima,Lena Pfaller,Alison Neal,Nelly R Hajizadeh,Qiuhong Zhao,Martin Beibel,Catherine Chung,Myriam Lemmens,Austin Sim,Mevion Oertli,Timothy Voorhees,Rebecca Bohnert,Nathan Denlinger,Yoann Gilbart,Lara Bontadelli,Laura Monovich,Jennifer Willert,Daniel Stover,Jingbo Gao,Li Li,Stefan Reinker,Ulrike Naumann,Hans D Menssen,Daniel Jones,Silvana Libertini,Jonathan E Brammer","doi":"10.1016/j.ymthe.2025.08.043","DOIUrl":null,"url":null,"abstract":"A Chimeric Antigen Receptor (CAR) positive CD30+/CD4+ T-cell lymphoma (TCL) manifested as a single oral ulceration 22 months after treatment with tisagenlecleucel (tisa-cel), an anti-CD19 CAR T-cell based therapy. TCL showed lentiviral integration in ANKHD1-EIF4EBP3, loss of function of TET2, and NTRK1 copy number gain, suggesting that genetic alterations unrelated to insertional mutagenesis contributed to lymphomagenesis. The patient remains in remission two years after radiotherapy. This is the only CAR+TCL case reported at Ohio State University James Comprehensive Cancer Center, out of 288 patients treated with CAR T-cells.","PeriodicalId":19020,"journal":{"name":"Molecular Therapy","volume":"38 1","pages":""},"PeriodicalIF":12.0000,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Isolated oral CD30+/CD4+ CAR+ T-cell lymphoma in long-term remission after radiotherapy.\",\"authors\":\"Evandro Bezerra,Ludmila Lupu,Marcos de Lima,Lena Pfaller,Alison Neal,Nelly R Hajizadeh,Qiuhong Zhao,Martin Beibel,Catherine Chung,Myriam Lemmens,Austin Sim,Mevion Oertli,Timothy Voorhees,Rebecca Bohnert,Nathan Denlinger,Yoann Gilbart,Lara Bontadelli,Laura Monovich,Jennifer Willert,Daniel Stover,Jingbo Gao,Li Li,Stefan Reinker,Ulrike Naumann,Hans D Menssen,Daniel Jones,Silvana Libertini,Jonathan E Brammer\",\"doi\":\"10.1016/j.ymthe.2025.08.043\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A Chimeric Antigen Receptor (CAR) positive CD30+/CD4+ T-cell lymphoma (TCL) manifested as a single oral ulceration 22 months after treatment with tisagenlecleucel (tisa-cel), an anti-CD19 CAR T-cell based therapy. TCL showed lentiviral integration in ANKHD1-EIF4EBP3, loss of function of TET2, and NTRK1 copy number gain, suggesting that genetic alterations unrelated to insertional mutagenesis contributed to lymphomagenesis. The patient remains in remission two years after radiotherapy. This is the only CAR+TCL case reported at Ohio State University James Comprehensive Cancer Center, out of 288 patients treated with CAR T-cells.\",\"PeriodicalId\":19020,\"journal\":{\"name\":\"Molecular Therapy\",\"volume\":\"38 1\",\"pages\":\"\"},\"PeriodicalIF\":12.0000,\"publicationDate\":\"2025-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ymthe.2025.08.043\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ymthe.2025.08.043","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

嵌合抗原受体（CAR）阳性CD30+/CD4+ t细胞淋巴瘤（TCL）在接受tisagenlecleucel（一种基于抗cd19 CAR - t细胞的治疗）治疗22个月后表现为单一口腔溃疡。TCL在ANKHD1-EIF4EBP3中表现出慢病毒整合，TET2功能丧失，NTRK1拷贝数增加，表明与插入突变无关的遗传改变参与了淋巴瘤的发生。该病人在放射治疗两年后仍处于缓解期。这是俄亥俄州立大学詹姆斯综合癌症中心在288名接受CAR - t细胞治疗的患者中报道的唯一一例CAR+TCL病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Isolated oral CD30+/CD4+ CAR+ T-cell lymphoma in long-term remission after radiotherapy.

A Chimeric Antigen Receptor (CAR) positive CD30+/CD4+ T-cell lymphoma (TCL) manifested as a single oral ulceration 22 months after treatment with tisagenlecleucel (tisa-cel), an anti-CD19 CAR T-cell based therapy. TCL showed lentiviral integration in ANKHD1-EIF4EBP3, loss of function of TET2, and NTRK1 copy number gain, suggesting that genetic alterations unrelated to insertional mutagenesis contributed to lymphomagenesis. The patient remains in remission two years after radiotherapy. This is the only CAR+TCL case reported at Ohio State University James Comprehensive Cancer Center, out of 288 patients treated with CAR T-cells.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Molecular Therapy 医学-生物工程与应用微生物

CiteScore

19.20

自引率

3.20%

发文量

357

审稿时长

3 months

期刊介绍： Molecular Therapy is the leading journal for research in gene transfer, vector development, stem cell manipulation, and therapeutic interventions. It covers a broad spectrum of topics including genetic and acquired disease correction, vaccine development, pre-clinical validation, safety/efficacy studies, and clinical trials. With a focus on advancing genetics, medicine, and biotechnology, Molecular Therapy publishes peer-reviewed research, reviews, and commentaries to showcase the latest advancements in the field. With an impressive impact factor of 12.4 in 2022, it continues to attract top-tier contributions.